Home page A B C D E F G H I K L M N O P Q R S T U V W X Y Z

Maximum Strength Mucinex D (guaifenesinpseudoephedrine


Udocheals.orgMucinex d drug interactions
7.19.2017 | Logan Miers
Mucinex d drug interactions
Maximum Strength Mucinex D (guaifenesinpseudoephedrine

2.5 mL PO every 4—6 hours, up to 10 mL/day.

guaifenesin 2400 mg/day PO; pseudoephedrine 240 mg/day PO.

Oral expectorant and sympathomimetic decongestant combination Primarily used for the temporary relief of congestion associated with the common cold.

1 capsule PO every 12 hours, up to 2 capsules/day.

1 tablet PO every 12 hours.

1 capsule PO every 12 hours.

The recommended dosage for Robitussin Cold Severe Congestion Liqui-Gels is 1 capsule PO every 4 hours, up to 4 capsules/day. No dosage recommendations are provided by the manufacturers for Sinutab Non-Drying Liquid Caps or Sudafed Non-Drying Sinus products.

restlessness / Early / Incidence not known anxiety / Delayed / Incidence not known insomnia / Early / Incidence not known drowsiness / Early / Incidence not known headache / Early / Incidence not known dizziness / Early / Incidence not known.

10 mL PO every 4—6 hours, up to 40 mL/day.

Pseudoephedrine-containing products should not be combined with MAOI therapy or within 2 weeks of such therapy.

Oral decongestants may cause dizziness, nervousness, insomnia, palpitations, urinary retention, and elevated blood pressure. In addition, oral decongestants, such as pseudoephedrine, should be used cautiously in patients who have insomnia or hypertension. The federal Omnibus Budget Reconciliation Act (OBRA) regulates medication use in residents of long-term care facilities. In general, dose selection for geriatric patients should be cautious, usually starting at the low end of the dosing range. According to the OBRA guidelines, cough, cold, and allergy medications should be used only for a limited duration (less than 14 days) unless there is documented evidence of enduring symptoms that cannot otherwise be alleviated and for which a cause cannot be identified and corrected. Geriatric patients 60 years and older are more likely to have decreased renal clearance of pseudoephedrine as well as adverse reactions to sympathomimetic amines. According to the Beers Criteria, oral decongestants such as pseudoephedrine are considered potentially inappropriate medications (PIMs) for use in geriatric patients with insomnia and should be avoided due to the potential for drug-induced CNS stimulant effects.

guaifenesin 2400 mg/day PO; pseudoephedrine 240 mg/day PO.

seizures / Delayed / Incidence not known stroke / Early / Incidence not known myocardial infarction / Delayed / Incidence not known arrhythmia exacerbation / Early / Incidence not known.

However, only 0.5% of a maternal dose would probably be ingested by an infant during breast-feeding within any 24 hours. It is not known whether guaifenesin is excreted into human breast milk. The decision should be made as to whether to discontinue breast-feeding or discontinue the product based upon the importance of the drug to the mother. Sympathomimetic adverse effects (irritability, excessive crying, and altered sleeping patterns) have been reported in a breast-fed infant following maternal administration of pseudoephedrine; symptoms resolved within 12 hours of drug discontinuation. The total amount of pseudoephedrine (measured by AUC) in milk is 2—3 times that of plasma. Guaifenesin; pseudoephedrine should be given cautiously to women who are breast-feeding. Peak milk concentrations of pseudoephedrine usually exceed those of maternal plasma. Lactating women may want to avoid breast-feeding during times of peak concentrations (i.e., within 1—2 hours after a dose) when possible. Pseudoephedrine is excreted into breast milk, with peak milk concentrations occur 1—1.5 hours after a maternal oral dosage. The American Academy of Pediatrics has considered the use of pseudoephedrine to be compatible with lactation.

1 tablet PO every 4—6 hours, up to 6 tablets/24 hours.

5 mL PO every 4—6 hours, up to 20 mL/day.

10 mL PO every 4—6 hours, up to 40 mL/day.

NOTE: Do not exceed recommended dosage limits for the specific product prescribed; the following are general guidelines:

1 tablet PO every 6 hours.

It is relatively contraindicated in patients with hyperthyroidism, diabetes mellitus, or peripheral vascular disease because sympathomimetics can exacerbate these conditions. Pseudoephedrine is also contraindicated for use in patients with closed-angle glaucoma and urinary retention due to prostatic hypertrophy.

1 tablet PO every 12 hours.

1 tablet PO every 12 hours.

2—5 years: guaifenesin 600 mg/day PO; pseudoephedrine 60 mg/day PO. 6—11 years: guaifenesin 1200 mg/day PO; pseudoephedrine 120 mg/day PO. < 2 years: Safety and efficacy have not been established.

2 tablets PO every 12 hours, up to 4 tablets/day.

1 tablet PO every 4—6 hours, up to 6 tablets/24 hours.

1 caplet PO every 12 hours, not to exceed 2 caplets in 24 hours.

2.5 mL PO every 4—6 hours, up to 10 mL/day.

Thank you. Your has been sent.

1 tablets PO every 12 hours, up to 2 tablets/day.

Decongestant and Expectorant Combinations Non-Opioid Antitussive and Decongestant Combinations Rx, OTC.

Not a Member? Register Now this page.

One-half tablet PO every 12 hours, up to 1 tablet/day.

One-half tablet PO every 12 hours, up to 1 tablet/day.

5 mL PO every 4—6 hours, up to 20 mL/day.

guaifenesin 2400 mg/day PO; pseudoephedrine 240 mg/day PO.

1 tablet PO every 12 hours; Max: 2 tablets/24 hours.

1—2 tablets PO every 12 hours, up to 4 tablets/day.

2 capsules PO every 4 hours, up to 8 capsules/day.

One-half tablet PO every 12 hours.

1 tablet PO every 12 hours, up to 2 tablets/day.

Use of fixed-dose guaifenesin; pseudoephedrine combination products in infants and children less than 2 years of age is not recommended; many products for guaifenesin; pseudoephedrine are not for use in children less than 6 years of age. In January 2008, the FDA issued a Public Health Advisory recommending that OTC cough and cold products not be used in infants and children less than 2 years. Read product labels carefully. The report estimated that 1,519 children less than 2 years of age were treated in emergency departments during 2004 to 2005 for adverse events related to cough and cold medications. The adverse effects of sympathomimetics such as pseudoephedrine can be severe, especially in infants and toddlers; CNS stimulation, increased blood pressure, and tachycardia may occur. If cough and cold products are used in children, labels should be read carefully, caution should be used when administering multiple products, and only measuring devices specifically designed for use with medications should be used. In October 2007, the FDA Nonprescription Drug Advisory Committee and the Pediatric Advisory Committee recommended that nonprescription cough and cold products containing pseudoephedrine, dextromethorphan, chlorpheniramine, diphenhydramine, brompheniramine, phenylephrine, clemastine, or guaifenesin not be used in children less than 6 years of age. In January 2007, the CDC warned caregivers and healthcare providers of the risk for serious injury or fatal overdose from the administration of cough and cold products to children and infants less than 2 years of age; some cases were due to inadvertent inappropriate use. Clinicians should thoroughly assess each patient's use of similar products, both prescription and nonprescription, to avoid duplication of therapy and the potential for inadvertent overdose.

Aldex GS, Ambi, Ambifed, Ambifed-G, Aquatab D, Congestac, D Feda II, Decongest II, Deconsal II, Defen LA, Desal II, Durasal II, Dynex, Entex T, ExeFen, ExeFen-IR, Guaifenex PSE-60, Guiatex II SR, Iosal II, Maxifed, Maxifed-G, Medent-LDI, Mucinex D, Poly-Vent IR, Respaire-30, Robitussin Severe Congestion, Sinutab, Sudafed Non-Drying Sinus, SudaTex-G, Zephrex.

It may increase renal clearance for urate and lower serum uric acid levels. Guaifenesin may also falsely elevate the VMA test for catechols. Guaifenesin; pseudoephedrine is contraindicated in individuals with known hypersensitivity to sympathomimetics. Guaifenesin may alter some laboratory tests. Products containing guaifenesin should be discontinued at least 48 hours prior to the collection of urine specimens for such laboratory tests. Guaifenesin may produce an increase in urinary 5-hydroxyindoleacetic acid and may therefore interfere with the interpretation of this diagnostic test for carcinoid syndrome.

Safety and efficacy have not been established.

Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed.

1—2 tablets PO every 12 hours.

Pseudoephedrine is primarily eliminated by renal excretion; pseudoephedrine should be used with caution in patients with renal impairment and a dosage reduction is warranted. Due to decreased elimination and potential pseudoephedrine drug accumulation, patients with renal failure may at increased risk for drug-related toxicity.

We do not record any personal information entered above.

Guaifenesin-containing products should not be used for persistent or chronic cough such as occurs with tobacco smoking, asthma, emphysema, or chronic bronchitis or any other condition where cough is associated with excessive secretions, unless under the supervision of a health care professional.

Separate multiple address with a comma.

Adequate or well-controlled pregnancy studies have not been done in humans. Use of guaifenesin; pseudoephedrine during pregnancy should be avoided unless the potential benefits outweigh the unknown potential risks to the fetus. Some sympathomimetic amines are associated with minor malformations in some animal species; however, human teratogenesis has not been suspected based on limited epidemiologic evidence. When administered to pregnant women, product formulations that also contain ethanol or other drugs should not be used. Both guaifenesin and pseudoephedrine are classified as pregnancy category C drugs.

One-half tablet (0.5 tablets) PO every 4—6 hours, up to 3 tablets/day.

1 tablet PO every 12 hours, up to 2 tablets/day.

Aldex GS: - Store at controlled room temperature (between 68 and 77 degrees F) Altarussin PE: - Store at room temperature (between 59 to 86 degrees F) Altex-PSE: - Storage information not listed Ambi: - Store at room temperature (between 59 to 86 degrees F) Ambifed : - Protect from light - Protect from moisture - Store at room temperature (between 59 to 86 degrees F) Ambifed-G: - Protect from light - Protect from moisture - Store at room temperature (between 59 to 86 degrees F) Ami-Tex PSE: - Storage information not listed Aquatab D: - Store at controlled room temperature (between 68 and 77 degrees F) Coldmist JR: - Avoid exposure to heat - Protect from moisture - Store at room temperature (between 59 to 86 degrees F) Coldmist LA : - Store at room temperature (between 59 to 86 degrees F) Congestac: - Store at room temperature (between 59 to 86 degrees F) D Feda II: - Store at controlled room temperature (between 68 and 77 degrees F) Decongest II : - Store at controlled room temperature (between 68 and 77 degrees F) Deconsal II: - Store at controlled room temperature (between 68 and 77 degrees F) Defen LA: - Store at controlled room temperature (between 68 and 77 degrees F) Desal II : - Store at controlled room temperature (between 68 and 77 degrees F) Drituss GP: - Avoid exposure to heat - Protect from moisture - Store at room temperature (between 59 to 86 degrees F) Durasal II : - Store at controlled room temperature (between 68 and 77 degrees F) Duratuss: - Storage information not listed Duratuss GP: - Avoid exposure to heat - Protect from moisture - Store at room temperature (between 59 to 86 degrees F) Dynex: - Store at room temperature (between 59 to 86 degrees F) Entex PSE: - Store at 77 degrees F; excursions permitted to 59-86 degrees F Entex T: - Store between 68 to 77 degrees F ExeFen: - Store at controlled room temperature (between 68 and 77 degrees F) ExeFen-IR: - Store at room temperature (between 59 to 86 degrees F) Guaidrine GP: - Avoid exposure to heat - Protect from moisture - Store at room temperature (between 59 to 86 degrees F) Guaidrine PSE: - Storage information not listed Guaifen PSE: - Storage information not listed Guaifenex GP: - Avoid exposure to heat - Protect from moisture - Store at room temperature (between 59 to 86 degrees F) Guaifenex PSE-120: - Storage information not listed Guaifenex PSE-60: - Store at controlled room temperature (between 68 and 77 degrees F) Guaifenex PSE-80: - Store at 77 degrees F; excursions permitted to 59-86 degrees F Guaifenex PSE-85: - Store at room temperature (between 59 to 86 degrees F) Guaimax D : - Storage information not listed Guaipax PSE: - Storage information not listed Guai-Vent-PSE: - Storage information not listed Guiatex II SR : - Store at controlled room temperature (between 68 and 77 degrees F) Iosal II : - Store at controlled room temperature (between 68 and 77 degrees F) Iotex PSE: - Storage information not listed Levall G: - Store at room temperature (between 59 to 86 degrees F) Maxifed: - Store at room temperature (between 59 to 86 degrees F) Maxifed-G: - Store at room temperature (between 59 to 86 degrees F) Medent-LDI: - Store at room temperature (between 59 to 86 degrees F) Miraphen PSE : - Storage information not listed Mucinex D: - Store between 68 to 77 degrees F Nasatab LA: - Store at room temperature (between 59 to 86 degrees F) Nomuc-PE : - Store at controlled room temperature (between 68 and 77 degrees F) PanMist JR: - Avoid exposure to heat - Protect from moisture - Store at room temperature (between 59 to 86 degrees F) PanMist LA: - Store at room temperature (between 59 to 86 degrees F) PanMist S: - Store at room temperature (between 59 to 86 degrees F) Poly-Vent IR: - Store at room temperature (between 59 to 86 degrees F) Profen Forte : - Store at room temperature (between 59 to 86 degrees F) Profen II: - Store at room temperature (between 59 to 86 degrees F) Pseudatex: - Protect from light - Store at 77 degrees F; excursions permitted to 59-86 degrees F Pseudo GG TR : - Avoid exposure to heat - Protect from moisture - Store at room temperature (between 59 to 86 degrees F) Pseudovent: - Store at room temperature (between 59 to 86 degrees F) Pseudovent-400: - Store at 77 degrees F; excursions permitted to 59-86 degrees F Pseudovent-PED: - Store at room temperature (between 59 to 86 degrees F) Q-Tussin PE: - Store at room temperature (between 59 to 86 degrees F) Respaire SR: - Store at controlled room temperature (between 68 and 77 degrees F) Respaire-30 : - Store at 77 degrees F; excursions permitted to 59-86 degrees F Robitussin PE: - Store at room temperature (between 59 to 86 degrees F) Robitussin Severe Congestion: - Protect from light - Protect from moisture - Store at room temperature (between 59 to 86 degrees F) Ru-Tuss DE: - Storage information not listed Ru-Tuss Jr.: - Protect from light - Protect from moisture - Store at room temperature (between 59 to 86 degrees F) Sinutab: - Protect from light - Protect from moisture - Store at room temperature (between 59 to 86 degrees F) Stamoist E: - Store at room temperature (between 59 to 86 degrees F) Sudafed Non-Drying Sinus: - Protect from light - Protect from moisture - Store at room temperature (between 59 to 86 degrees F) Sudal SR: - Store at room temperature (between 59 to 86 degrees F) SudaTex : - Store at room temperature (between 59 to 86 degrees F) SudaTex-G : - Store at room temperature (between 59 to 86 degrees F) Touro LA: - Store at room temperature (between 59 to 86 degrees F) Touro LA-LD: - Store at room temperature (between 59 to 86 degrees F) Triaminic Chest and Nasal Congestion: - Store at room temperature (between 59 to 86 degrees F) Tusnel Pediatric: - Protect from light - Store at room temperature (between 59 to 86 degrees F) WE Mist II LA: - Store at 77 degrees F; excursions permitted to 59-86 degrees F Zephrex: - Store at room temperature (between 59 to 86 degrees F).

Guaifenesin-containing products should be used in patients with a high temperature only under the direction of a physician. A fever may be indicative of a serious condition.

Guaifenesin; pseudoephedrine products are administered orally.

One-half caplet PO every 12 hours, not to exceed 1 caplet in 24 hours.

One-half tablet (0.5 tablets) PO every 4—6 hours, up to 3 tablets/24 hours.

Considerable caution should be used in patients with controlled or mild hypertension, heart failure, cardiomyopathy, acute cardiac arrhythmias (tachycardia), or other cardiac disease. Guaifenesin should not be used for a cough that is specifically associated with heart failure or ACE inhibitor therapy. Since pseudoephedrine is a vasoconstrictor and may increase heart rate via sympathomimetic effects, it should be avoided in patients with uncontrolled or severe hypertension or severe coronary artery disease (including history of myocardial infarction, acute myocardial infarction, or angina). Although considered safe in the general population of controlled hypertensives, increased blood pressure (especially systolic hypertension) has been reported in individual patients receiving pseudoephedrine. Well-controlled hypertensive adult patients receiving pseudoephedrine at recommended doses (240 mg/day PO) generally do not appear at risk for significant elevations in blood pressure; however, small increases in blood pressure and heart rate may occur.

Aldex GS/Ambi/Ambifed/Ambifed-G/Congestac/Dynex/Entex T/ExeFen/ExeFen-IR/Guaifenesin, Pseudoephedrine/Guaifenesin, Pseudoephedrine Hydrochloride/Maxifed/Maxifed-G/Medent-LDI/Poly-Vent IR/SudaTex-G/Zephrex Oral Tab: 1200-90mg, 190-30mg, 375-60mg, 380-60mg, 400-20mg, 400-30mg, 400-40mg, 400-60mg, 780-80mg Ambi/Guaifenesin, Pseudoephedrine/Guaifenesin, Pseudoephedrine Hydrochloride/Maxifed-G/Mucinex D/SudaTex-G Oral Tab ER: mg, 580-60mg, 600-60mg Respaire-30 Oral Cap: 150-30mg.

1—2 capsules PO every 12 hours, up to 4 capsules/day.

CrCl less than 30 mL/minute: Reduce the initial pseudoephedrine dosage by 50% (Adult Max: 120 mg/day PO), to avoid potential drug accumulation and toxicity.

Note that some guaifenesin; pseudoephedrine syrups contain alcohol. Oral solution: Administer using a calibrated spoon, cup, or syringe to ensure accurate dosing.

Send the page " " to a friend, relative, colleague or yourself.

1—2 tablets PO every 12 hours, up to 4 tablets/day.

hallucinations / Early / Incidence not known psychosis / Early / Incidence not known sinus tachycardia / Rapid / Incidence not known premature ventricular contractions (PVCs) / Early / Incidence not known angina / Early / Incidence not known hypertension / Early / Incidence not known palpitations / Early / Incidence not known supraventricular tachycardia (SVT) / Early / Incidence not known.

Regular-release tablets: Administer last dose 2 hours before bedtime to minimize insomnia due to pseudoephedrine. For patients with difficulty swallowing, extended-release capsules may be opened and mixed with jam or jelly and swallowed without chewing. Extended-release tablets: Swallow whole; do not crush or chew. Scored tablets may be divided in half. Extended-release capsules: Swallow whole; do not crush or chew.

Mucinex d drug interactions